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Abstract
Bluetongue virus is the type species of the genus Orbivirus, family Reoviridae. Bluetongue
viruses (BTV) are transmitted between their vertebrate hosts primarily by biting midges
(Culicoides spp.) in which they also replicate. Consequently BTV distribution is dependent
on the activity, geographic distribution, and seasonal abundance of Culicoides spp. The
virus can also be transmitted vertically in vertebrate hosts, and some strains/serotypes can
be transmitted horizontally in the absence of insect vectors. The BTV genome is composed
of ten linear segments of double-stranded (ds) RNA, numbered in order of decreasing size
(Seg-1 to Seg-10). Genome segment 2 (Seg-2) encodes outer-capsid protein VP2, the
most variable BTV protein and the primary target for neutralising antibodies. Consequently
VP2 (and Seg-2) determine the identity of the twenty seven serotypes and two additional
putative BTV serotypes that have been recognised so far. Current BTV vaccines are sero-
type specific and typing of outbreak strains is required in order to deploy appropriate vac-
cines. We report development and evaluation of multiple ‘TaqMan’ fluorescence-probe
based quantitative real-time type-specific RT-PCR assays targeting Seg-2 of the 27+1 BTV
types. The assays were evaluated using orbivirus isolates from the ‘Orbivirus Reference
Collection’ (ORC) held at The Pirbright Institute. The assays are BTV-type specific and can
be used for rapid, sensitive and reliable detection / identification (typing) of BTV RNA from
samples of infected blood, tissues, homogenised Culicoides, or tissue culture superna-
tants. None of the assays amplified cDNAs from closely related but heterologous orbi-
viruses, or from uninfected host animals or cell cultures.
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Introduction
Bluetongue (BT), is a non-contagious, economically important disease of ruminants (particu-
larly sheep, cattle and some deer species), caused by the bluetongue virus (BTV), which is
transmitted primarily by adult Culicoidesmidges [1, 2]. The virus can also be transmitted verti-
cally in vertebrate hosts, and some strains/serotypes can be transmitted horizontally in the
absence of insect vectors [3]. The clinical signs of infection can include fever, depression, lame-
ness, oedema of the lips, tongue and head, conjunctivitis, coronitis, excessive salivation, nasal
discharge, hyperaemia and pain at muco-cutaneous junctions (such as the gums and vulva)
and death. In pregnant animals the virus can cross the placenta, sometimes causing teratogenic
effects or abortion including canines [4, 5]. Following recovery, animals may show long-lasting
secondary effects, including reducedmilk yield or reduced weight-gain, severe wool break and
temporary infertility. BT has been listed by theWorld Organisation for Animal Health as an
important transboundary animal disease [6].
BTV genome has 10-segments of linear double-stranded (ds) RNA (identified as genome
segments 1 to 10 [Seg-1 to Seg-10] in order of decreasing size), most of which (except Seg-8
and 9) encode a single viral protein [7–9]. The genome segments are packaged within a capsid
composed of three concentric layers of proteins. The outer-most capsid-layer is composed of
180 copies of protein VP2 and 360 copies of VP5 (encoded by Seg-2 and Seg-6, respectively).
There are 27 known serotypes of BTV (and two additional putative serotypes—PeterMertens—
unpublished data) [10–16] the identity of which is determined by the specificity of reactions
between the outer capsid proteins, primarily VP2, and neutralising antibodies that are generated
by the vertebrate host (Table 1). Full-genome sequence analyses confirm that VP2 / Seg-2 are
the most variable of the BTV proteins / genome-segments [17–20] separating isolates into 29
distinct clades that accurately reflect virus serotype [10, 21]. Studies of reassortant viruses and
neutralisation escapemutants indicate that sequence variations in VP5 / Seg-6 can also influ-
ence the overall specificity of these neutralisation reactions, although to a lesser extent than VP2
[22–24].
The structural proteins of the BTV core particle (VP1, VP3, VP4, VP6 and VP7), as well as
the non-structural proteins (NS1 to NS5) are all more highly conserved than VP2 or VP5,
reflectingmembership of the same Bluetongue virus species / serogroup [15, 25, 26]. However,
these analyses have also identified sequence variations in each of the BTV genome segments
that group the virus isolates from different geographic regions into ‘major’ eastern and western
topotypes (containing isolates from South East Asia, India, China or Australia, or from Africa
and North or South America, respectively). These topotype variations are also detected as vari-
ations in Seg-2 and Seg-6 (encoding the outer capsid proteins) but within the individual BTV
serotypes. There is also evidence for a further ‘far-eastern’ topotype containing viruses from
China and Australia, as well distinct groups represented by isolates of the recently discovered
serotypes BTV-25 and BTV-26 [10, 18, 27, 28].
Prevention and control of bluetongue relies on preventing the initial introduction of infec-
tion into a region or country that contains susceptible hosts and vectors, or on vaccination of
susceptible livestock [29], using either live modified viruses, or tissue culture derived and
chemically inactivated virus preparations [30–32]. The ruminant host’s response to vaccination
is serotype specific and rapid, therefore accurate and reliable serotype identification is an
important part of any surveillance and control programme, to support the design and rapid
deployment of appropriate vaccines. Diagnostic systems for BTV are also needed to demon-
strate absence of the virus in individual animals or animal products (for safe movements/
export/import), as well as for declaration of a ‘virus free’ status, after outbreaks in non-endemic
countries or zones [6].
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The bluetongue viruses were initially identified and distinguished from the other orbiviruses
by serologicalmethods, including Agar gel immuno-diffusion (AGID) tests and enzyme-linked
immunosorbent assay (ELISA) [33]. However, these methods are slow, labour intensive and
require virus isolation and/or access to standard reagents (antibodies and antigens) that may
themselves represent a potential biosecurity risk.
BTV RNA can be detected by amplification in conventional or real-time RT-PCR assays.
Several of the ‘conserved’ BTV genome segments have been used as targets for conventional
RT-PCR assays, including the genes encodingVP1, VP3, VP7, NS1, NS2 and NS3 [34–36].
Similarly, several BTV genome segments have been targeted for real-time RT-PCR assays for
detection of BTV RNA, including those encodingVP1 [37, 38]; NS1 [38], NS2 [39], VP6 [40]
and NS3 genes [41]. Since none of these proteins determine BTV serotype hence these targets
cannot be used to ‘type’ BTV isolates.
Virus neutralisation tests (VNT) and serumneutralisation tests (SNT) are the “gold stan-
dard” method for BTV serotyping. However, serological procedures are expensive and time-
consuming and are often associated with poor sensitivity. Unlike conventional PCR-based
Table 1. Isolation details of the known serotypes of BTV.
Serotypes Year Origin Species isolated from References
1 1958 Biggarsberg—South Africa Sheep [54]
2 1958 Vryheid—South Africa Sheep [54]
3 1944 Cyprus Sheep [70]
4 1900 Cape Province—South Africa Sheep [71]
5 1953 Machadodorp—South Africa Sheep [54]
6 1958 Vryheid—South Africa Sheep [54]
7 1955 Utrecht—South Africa Sheep [54]
8 1937 Onderstepoort—South Africa Sheep [54]
9 1942 Pretoria—South Africa Sheep [54]
10 1956 Portugal Sheep [54]
11 1944 Beaufort -West—South Africa Sheep [54]
12 1941 Beaufort -West—South Africa Cattle [54]
13 1959 Transvaal/Natal—South Africa Unknown [54]
14 1959 Transvaal/Natal—South Africa Unknown [54]
15 1960 Ermelo district—South Africa Cattle [54]
16 1959 West Pakistan Sheep [72]
17 1979 United States Unknown [73]
18 1976 Republic of South Africa (RSA) Sheep (Erasmus, Unpublished)
19 1976 RSA Sheep (Erasmus, Unpublished)
20 1978 Australia Culicoides [74]
21 1980 Australia Cattle [74]
22 1992 RSA Culicoides [75]
23 1987 Australia Cattle [76]
24 1992 RSA Sheep (Erasmus, Unpublished)
25 2007 Toggenburg—Switzerland Goats [77]; [78]
26 2010 Kuwait Sheep [14]
27 2014 Corsica, France Goats [13]
28 2014 Middle-East Unknown Nomikou et al—unpublished
29 2013 RSA Alpaca [12]
Part of the table was adapted from Wright, I.M., M.V.Sc thesis [12].
doi:10.1371/journal.pone.0163014.t001
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approaches, quantitative real-time PCR chemistries use fully automated detection systems that
eliminate the need for post-amplification sample handing, hence displaying very high sensitivi-
ties and broad dynamic ranges after optimization particularly for mixed infections.
Highly sensitive and specificmolecular ‘typing’ assays, targeting Seg-2 (including conven-
tional, RT-PCR, sequencing and probe-hybridisationmethods) have previously been reported
for identification of 26 BTV and 9 AHSV serotypes [21, 42, 43]. However, the detection of
novel serotypes and further introductions of exotic serotypes and topotypes into new geo-
graphic areas, requires a complete set of Seg-2 specific TaqMan assays for accurate, sensitive
and specific serotype identification of all of the known BTV types, to help in surveillance as
well as the rapid design and implementation of effective vaccination and control programmes.
Full-length Seg-2 sequence data frommultiple isolates of individual types, including strains
belonging to both eastern and western topotypes, were used to design a most complete set of
‘serotype-specific’ primers and probes to detect and identify Seg-2 from all known serotypes of
BTVwith the exception of putative BTV-28. The specificity of each assay was evaluated using a
wide range of BTV isolates from the Orbivirus Reference Collection (ORC) [44] at The Pirb-
right Institute (TPI).
The real-time RT-PCR assays that are described in this manuscript provide rapid and reli-
able BTV serotype identification and are suitable for high through put diagnostic systems.
They are not invalidated by mixed infections and have been used to identify incursions of mul-
tiple BTV types into Europe, India, Australia, Middle East and the USA [10, 11, 45–47].
Materials and Methods
Primers and probe design
Seg-2 nucleotide sequences of BTV reference strains that were generated during this study
using the previously describedmethod [25] and nucleotide sequences that are already available
in the public domain (GenBank) were used to design primers and probes for the detection and
typing of BTV RNA (S1 Table). For this the Seg-2 sequences were aligned and analysed collec-
tively and separately for each of the 27+1 BTV serotypes usingMEGA v. 6 [48]. Unique regions
in Seg-2 were identified for each serotype, as targets for the primers and probes (Table 2). The
primers and probes for each serotype specific assay, were also checked using the available
sequence data to ensure no cross-reactions with the genome segments of related BTV serotypes
or any of the 29 heterologousOrbivirus species [25, 44, 49–52]. Probes were labelled at their 5’
and 3’ ends with 6-carboxyfluorescein (6-FAM) and Black Hole Quencher-1 (BHQ-1) respec-
tively. All oligonucleotides were synthesised by Eurogentec, UK. Primers were PAGE purified
and probes were HPLC purified.
Virus isolates
A total of 1063 BTV isolates (fromORC) representing all 27+1 of the known BTV serotypes,
and strains from different areas of the world, were used for evaluation of the real-time RT-PCR
assays (S2 Table) [44]. OtherOrbivirus species isolates were also used to assess the specificity
of the BTV-serotype-specific assays. All of the isolates were grown in BHK-21 clone 13 cells
(European Collectionof Animal cell Cultures [ECACC– 84100501]), Vero cell monolayers
(ECACC– 84113001), or in KC cells derived from Culicoides sonorensis [53]. Infected KC cells
were harvested 7 days post infection, whereas the infectedmammalian cells were harvested
when ~80% cytopathic effect (CPE) was observed. In these studies the virus isolates were gen-
erated from diagnostic samples (blood and/or spleen or lung), taken from naturally infected
animals as part of normal veterinary surveillance in the respective countries. Established refer-
ence strains of BTVwere also included in these studies [54]. Neither animals were infected nor
BTV Typing qRT-PCR Assays
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Table 2. List of primers and probes for BTV type-specific assays.
Oligo Name Oligo Sequence (5’-3’) Pd Size (bp) eastern (e) or western (w)
BTV-1 (eastern + western strains)
BTV-1/2604-2627P(w) CCGATCACACATCCGAACAAATGC 78 w
BTV-1/1632-1662P(e) CAACGACRGAAYGATGAYCCRATGGTGAAAC 112e
BTV-1/2575-2597F(w) GTATTTCTGAYGGTATTGTYTGG
BTV-1/1599-1623F(e) GCYAAATTRCGAATCAARCATRGYG
BTV-1/2653-2633R(w) TCATCAGATACCTCGATCGCT
BTV-1/1711-1689R(e) GTTARCCTCTGCAAYACAATAGG
BTV-2 (eastern + western strains)
BTV-2/1455-1428P(w) CATTCCATCCACCATCTATAATTTCCCC 127w
BTV-2/116-139P(e) CCAAGATGGCCGACATGACGTATC 110e
BTV-2/1401-1421F(w) GATGAYRYAARTAYTCTGAG
BTV-2/60-81F(e) GAGCATTTGTTGAAARGTTATG
BTV-2/1528-1503R(w) GYATCYYTTTCGAARTCRATTGTRAG
BTV-2/170-148R(e) GATATCRAAYGCGTACATYTCTG
BTV-3 (western strains)
BTV-3/S2/656-688Pw CYCCRCAGTTTCAYACAATACAGAGGAACCATC 99w
BTV-3/S2/619-640Fw GARCGGTTRTCRACGGAWGARG
BTV-3/S2/718-694Rw TATCRTAAGCGTTATCTCCTARCYG
BTV-4 (western strains)
BTV-4/S2/2502-2529P2 TACCTGTTGTGACRTCCAAGTTGGACAC 87w
BTV-4/S2/2470-2488F2 GAACACGAAGATATCGCAG
BTV-4/S2/2557-2532R2 GCATARAGAAGCTARATGTATCTTCA
BTV-5 (western strains)
BTV-5/S2/36-61Pw CCGATWTTKCGRTCGAGCCAAGTTCC 93w
BTV-5/S2/08-26Fw GCTTCTCAGGATGGATGAG
BTV-5/S2/101-79Rw CARRTCRAYCTTAAYRTCRTAYC
BTV-6 (western strains)
BTV-6/2086-2061P CACCTTGAYTCATCCACACTACGAAC 111w
BTV-6/2001-2023F GTCGATGTYACACAGTTGATCGT
BTV-6/2112-2090R TAGCACGTCTAATCGTTTCTATG
BTV-7 (western strains)
BTV-7/S2/1635-1660Pw CCACAATCTAGACCCGGCAATATCGC 96w
BTV-7/S2/1608-1631Fw AGTATGTGAGACGTCAATCTCAGA
BTV-7/S2/1704-1682Rw GTCTAATAGGTCCGCAGCTTTAG
BTV-8 (western strains)
BTV-8/132-106P(w) CGGGCTCATCACCTTCCTCTTCAACAC 87w
BTV-8/72-93F(w) GATGGRTATGATTACATCATTG
BTV-8/159-138R(w) GAATTYCTGTYACATCGTGTCG
BTV-9 (eastern + western strains)
BTV-9/1703-1727P(w) CTTATATGACACTCGCCCTGCCATC 106w
BTV-9/1735-1762P(e) CAACCCTATCAATGAGACAACGCCAGAC 97e
BTV-9/1673-1694F(w) GGTTATGCTTCAATTACGAACG
BTV-9/1706-1724F(e) GTATGATACCAGGCCAGCG
BTV-9/1779-1756R(w) GGGTCTTATGTAGGGATGTCTGTG
BTV-9/1803-1783R(e) GTTCATTTTGAGGATCATCCA
BTV-10 (western strains)
BTV-10/S2/1519-1552Pw YCTTGGYNCGCGYTCTGAATTAGTATTYCCRCCY 107w
(Continued )
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Table 2. (Continued)
Oligo Name Oligo Sequence (5’-3’) Pd Size (bp) eastern (e) or western (w)
BTV-10/S2/1470-1488Fw TATTRACWACWGAACCAAACCT
BTV-10/S2/1577-1557Rw GYGARTTRATCCRTTTGTCAT
BTV-11 (western strains)
BTV-11/S2/1540-1573Pw YGTGCTCCCAAGTTATTTCGATCAATGGATCTAC 107w
BTV-11/S2/1510-1530Fw GGATGCGYAYYTGAATATTAG
BTV-11/S2/1617-1596Rw ATCTCTCCATGAGTTATTCGCA
BTV-12 (western strains)
BTV-12/S2/1101-1077Pw CTCCACCATATGCGCCAACGATAGC 137w
BTV-12/S2/999-1019Fw ATACAATTCAGGCTATCCRGA
BTV-12/S2/1136-1116Rw CAATGATYGTTCCTCGTAAGC
BTV-13 (western strains)
BTV-13/S2/1206-1175Pw CTTATATCCCTCACGTACGCTCCAYTCATACC 78w
BTV-13/S2/1147-1169Fw GGTGACGTYTATTATAAATTGCG
BTV-13/S2/1225-1207Rw GGCGATCCARATCYCGWGG
BTV-14 (western strains)
BTV-14/S2/2663-2683Pw CCGGCTTCGCGCGAGRTTYCC 142w
BTV-14/S2/2616-2636Fw GCCATTGARTTTTCTGAYGAYAG
BTV-14/S2/2758-2734Rw TCWGTATAYGCCTTAACYGCTCT
BTV-15 (western strains)
BTV-15/S2/130-105Pw CCCTCCCGATAAAGCGACCATATTCC 148w
BTV-15/S2/29-47Fw CCTGTGAGCGTGATCGAAC
BTV-15/S2/177-156Rw CTTACACCTATGTTTCGCACTC
BTV-16 (eastern + western strains)
BTV-16/1291-1264P(W) CCTTCGTTGCTGGCTCTCCCTCTAGATC 116w
BTV-16/1291-1264P(e) CCTTCGTTGCRGGCTCTCCTTCTAAGTC 127e
BTV-16/1221-1243F(W) GCGAGAGCAAGAGAAGTATATCG
BTV-16/1193-1213F(e) GACCTGAATATAAACCGCGAG
BTV-16/1337-1319R(W) GATGTTCGATACGTCTGGG
BTV-16/1320-1297R(e) ATTAATCAATTCGTACTCCCAGTG
BTV-17 (western strains)
BTV-17/S2/2224-2254Pw CCTCCCTCTGATGTTCCTTGTTCATGATAAC 137w
BTV-17/S2/2178-2202Fw TGCTRAAAGAGATCAAATTTGTRCGG
BTV-17/S2/2315-2295Rw ACTTGATCGTATCGTCAAACA
BTV-18 (western strains)
BTV-18/S2/387-414Pw CATGTACCATCACGGATAAGCCACGCCC 94w
BTV-18/S2/357-381Fw GATTATCAACCACTTAAGGTCGACG
BTV-18/S2/451-425Rw GCTCTCTTTGCGTGTAACCTTACCGTG
BTV-19 (western strains)
BTV-19/S2/2378-2346Pw CCAAACCTATTATARTACGCACCRAGCTCAACC 97w
BTV-19/S2/2313-2336Fw AGTGTTGRTATCRCATAAATTACG
BTV-19/S2/2410-2379Rw GGAAAGTYAGATGCGAAATYARRGAAGTCAAT
BTV-20 (western strains)
BTV-20/S2/1876-1902Pw CCGTAAAACCGCTTTGATGCTGATGGC 90w
BTV-20/S2/1838-1856Fw GCAATATGTCCGCATGCTG
BTV-20/S2/1928-1909Rw GCTCCGGGCTTAATTTTTCG
BTV-21 (eastern strains)
BTV-21/S2/1613-1636P CGCTCAACGTAAAGCAGATGACCC 102e
(Continued )
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Table 2. (Continued)
Oligo Name Oligo Sequence (5’-3’) Pd Size (bp) eastern (e) or western (w)
BTV-21/S2/1584-1603F GCCAGATTAAAGATAACGCA
BTV-21/S2/1686-1669R GTAAATCGATAGGGTCCG
BTV-22 (western strains)
BTV-22/S2/1101-1077Pw CTCCACCAGATACGCCACCGATAAC 111w
BTV-22/S2/1013-1032Fw ATCTCAAGCGGTCAAACAGA
BTV-22/S2/1124-1148Rw CCATTTCACAYGCTATTATAGTTCC
BTV-23 (eastern strains)
BTV-23/S2/92-118P CGAYGTAAGCACACGYATCGATGAACC 88e
BTV-23/S2/60-81F GCGGARYTGTTAGATGGCTATG
BTV-23/S2/148-126R GGAATTTGWGYRACRTCATGACG
BTV-24 (western strains)
BTV-24/S2/1944-1973Pw CATCAGACTTACAYGCACCCGAARATAAAY 115w
BTV-24/S2/1901-1919Fw GAACTAYGAGAAGCTTAYR
BTV-24/S2/2016-1994Rw GCGAAAARTCYYTCATATCTA
BTV-25 (western strains)
BTV-25/S2/2576-2605P CCCTCCCAATAACACATCCAGAGAAGTGCC 90w
BTV-25/S2/2554-2571F TTATCGGACTCGCTCGTT
BTV-25/S2/2644-2622R GTGGATTCAACTTATTATCTCCG
BTV-26 (eastern strains)
BTV-26/S2/1796-1827P1 CGAGAGGACTTCGCTATGCTAACACATTACGC 97e
BTV-26/S2/1752-1771F1 GTTATAGGCAGCAGCAATCT
BTV-26/S2/1849-1831R1 GCATATATCCCTTTCACCT
BTV-27 (western strains)
BTV-27/S2/1392-1420P CAACGGCATGCGTGATGATATTATACGGC 116w
BTV-27/S2/1334-1354F GCAAATCACAAGAAAAAGAAG
BTV-27/S2/1450-1423R GTAACTTCAAGCTTTCCTGGCG
BTV-29 (western strains)
BTV-29/S2/1541-1572P CATCTCGATAACCGCAATCACCTAGTGATGCC 140w
BTV-29/S2/1502-1522F GAAAAGAACATCTTCAACATG
BTV-29/S2/1642-1615R GATCTCAGTCGTGGTTACTCT
Additional list of primers and probes for BTV type-specific assays
BTV-1 (eastern + western strains)
BTV-1/2604-2627P(w) CCGATCACACATCCGAACAAATGC 78w
BTV-1/1630-1662P(e)r CASAACGACRGAATGAYGAYCCRATGGTGAAAC 121e
BTV-1/2575-2597F(w)r GTATTTCTGAYGGTATYGTYTGG
BTV-1/1590-1615F(e)r ATGTTTAAYGCYAARTTRCGAATYAA
BTV-1/2653-2633R(w)r TCATCAGAYACCTCGATCGCY
BTV-1/1711-1689R(e) GTTARCCTCTGCAAYACAATAGG
BTV-4 (eastern strains)
BTV-4/S2/1454-1430P(e) CCGCTCTTGATCCCACCCACCTTGA 125e
BTV-4/S2/1379-1400F(e) TTGTGTAAAGTGGATGAGGAGA
BTV-4/S2/1504-1477R(e) GAAGTCTATCGTCAAAAGGTTAGGGGCT
BTV-12 (western strains)
BTV-12/S2/1101-1077Pw CTCCACCATATGCGCCARCGATAGC 137w
BTV-12/S2/999-1019Fw ATACAATYCAGGCYATCMRGA
BTV-12/S2/1136-1116Rw CAATGATYGTTCCTCGTAAGC
BTV-21 (eastern strains)
(Continued )
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samples were taken from animals specifically for these studies, hence further ethical approval
was not sought.
RNA isolation
dsRNA was extracted, either from tissue culture supernatant, blood or other clinical samples,
using a MagVetTM universal purification kit (KingfisherTM, Life Technologies), or from BTV
infected cells (using Trizol Reagent1, Invitrogen, UK) [55]. In the first method, 100 μl of
infected-tissue-culture supernatant/blood/clinical sample was added to 250 μl of the lysis buffer
(NM1). Total nucleic acid (80 μl) was extracted from this solution using the KingfisherTM plat-
form, with magnetic beads and KingfisherTM, automates. Each of the isolates was handled with
care to avoid any cross-contamination. Total nucleic acid from uninfected tissue culture super-
natants, sheep blood or homogenisedCulicoides was also extracted using KingfisherTM (Life
Technologies) system.
RT-PCR reactions
RT-PCR reactions were performed as describedpreviously by [56]. Briefly, a fragment of the
targeted genome segment was amplified with different primers-probe sets using SuperScript
III/ Platinum Taq One-Step qRT-PCR Kit (Invitrogen, UK). RNA samples were always heat
denaturated (95°C for 3 min) prior to addition to the reactionmix [37]. Amplification was car-
ried out in MX3005p (Stratagene, UK) using the conditions: 55°C for 30 min, 95°C for 10 min
followed by 45 cycles of 95°C for 15 s and 60°C for 1 min. Fluorescence was measured during a
60°C annealing/extension step. Cycle threshold (Ct) values were measured as the point at
which the sample fluorescence signal crossed a threshold value (the background level). Nega-
tive results (for assays that did not exceed this level of signal) are reported as ‘No Ct’. All pre-
cautions were taken to avoid accidental contamination. The composition of the individual
optimised assays using either one or two sets of primers and probes is presented in Table 3.
Evaluation of RT-PCR assays for diagnostic specificity
A panel of (1063) isolates representing BTV serotypes 1 to 24, -26, -27 and -29, from different
geographical locations, were obtained from the ORC (S2 Table; [44] and tested in each case in
triplicate. The Seg-2 based type-specific assays were tested in vitro with both homologous and
heterologous serotypes to ensure diagnostic specificity and sensitivity. Isolates for BTV-25, and
-28 were not yet available from the ORC for testing in vitro, so the primers and probes for
BTV-25 were tested against them by sequence comparisons only, while for BTV-28 Seg-2
sequence data was not available for design of primers.
Representative isolates of otherOrbivirus species, includingAfrican horse sickness (AHSV),
Epizootic haemorrhagic disease virus (EHDV), Equine encephalosis virus (EEV) and Peruvian
horse sickness virus (PHSV) (as listed in S2 Table), were used to evaluate and confirm the diag-
nostic specificity the BTV-specific assays. The typing assays are also used extensively in the
European and OIE reference laboratory at Pirbright and by colleagues in laboratories in the
Table 2. (Continued)
Oligo Name Oligo Sequence (5’-3’) Pd Size (bp) eastern (e) or western (w)
BTV-21/2582-2601Pe CCTCCCAATAACGCATCCGC 75e
BTV-21/2562-2579Fe ACTGAGGGATTAGTTTGG
BTV-21/2637-2617Re GRTCATCRCAAATTTCAATSG
doi:10.1371/journal.pone.0163014.t002
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Americas, Asia, Europe and Australasia to identify the serotype of novel BTV isolates [10, 46,
47, 57–59] (S2 Table). To ensure that no false positives are caused by cross-reactions with the
host-species, total nucleic acid was extracted and tested from uninfected BHK, Vero and KC
cell-culture supernatants, sheep and cattle blood and homogenisedC. sonorensis, with uni-
formly negative results (S2 Table).
Evaluation of sensitivity and efficiency of the assays
The analytical sensitivity of the Seg-2 type-specific assays for the European serotypes (BTV-1,
-2, -4, -6, -8, -9, -11, and -16) were assessed using a dilution series of the quantified dsRNA
genome of reference strains of each BTV serotype (as listed in S1 Table). Additionally, this
selection of the assays for the European serotypes were also assessed for their sensitivity and
efficiency, using a recombinant plasmid DNA having insert sizes ranging from 78–127 bps
(Seg-2 specific amplicons for each of the eight European serotypes).
The dsRNA standards were prepared as follows: viral dsRNA (of RSArrrr/01 or other refer-
ence strains) was extracted as previously described [55], assessed for any ssRNA remains in 1%
agarose gel electrophoresis and the concentration of dsRNA was determinedwith NanoDrop
(Thermo Fisher Scientific,USA). To test analytical sensitivity, a 10-fold dilution series of
dsRNA (1010 to 10° copies per μl) was made in a sample of RNA extracted from uninfected
Table 3. Composition of reaction mixes for one-step RT-PCR reaction with one set of primers and
probe (3a) and two sets of primers and probes (3b).
Table 3a—One-step RT-PCR reaction mix with one set of primers and probe
Reagent Amount (μl)
Forward primer (10 pm/μl-1) 1
Reverse primer (10 pm/μl-1) 1
Probe (5 pm/μl-1) 1
MgSO4 (50mM) 1
ROX (1/10 dilution) 0.5
1Superscript1 III RT/Platinum1 Taq Mix 2x reaction mix 12.5
Nuclease free water (μl) 5
dsRNA (μl) 3
Total volume (μl) 25
Table 3b2- One-step RT-PCR reaction mix with two sets of primers and probes
Forward primer 1 (10 pm/μl-1) 1
Reverse primer 1 (10 pm/μl-1) 1
Probe 1 (5 pm/μl-1) 0.5
Forward primer 2 (10 pm/μl-1) 1
Reverse primer 2 (10 pm/μl-1) 1
Probe 2 (5 pm/μl-1) 0.5
MgSO4 (50mM) 1
ROX (1/10 dilution) 0.5
Superscript1 III RT/Platinum1 Taq Mix 2x reaction mix 12.5
Nuclease free water (μl) 3
dsRNA (μl) 3
Total volume (μl) 25
1SuperScript III/ Platinum Taq One-Step qRT-PCR Kit (Invitrogen, UK).
2The duplex format of the assay is for use with sets of primers and probes for the same serotype (eastern
and western strains).
doi:10.1371/journal.pone.0163014.t003
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BHK cells supernatant, then tested in triplicate. The number of dsRNA copies was calculated
with the formula: Y = (X/(a x 680)) x 6.022 x 1023, where: Y = molecules/μl; X = g/μl dsRNA;
a = viral genome length in nucleotides; 680 is the average molecular weight per nucleotide of
dsRNA.
To test analytical sensitivity of the Seg-2 type-specific assay using recombinant plasmid
DNA, a 10-fold dilution series of plasmid DNA (1010 to 10° copies per μl) was made in TE dilu-
tion buffer and then tested in triplicate. The number of plasmid DNA copies were calculated
with the formula: Y = (X/(a x 660)) x 6.022 x 1023, where: Y = molecules/μl; X = g/μl dsDNA;
a = plasmid plus insert length in nucleotides; 660 is the average molecular weight per nucleo-
tide of dsDNA.
Viral dsRNA dilution series were used to generate standard curves by linear regression
methods, setting Ct values as dependent, and the dsRNA concentrations as independent vari-
ables. The slope of the standard curves for the optimised serotype-specific assays, were then
used to estimate the efficiencyof the individual assays in detection of each of the reference
strain. The efficiencywas calculated by the formula E% = (10−1/slope−1)×100. Efficiencies of
Seg-2 assays were estimated on the basis of standard curves plotting Ct values against corre-
sponding log plasmid copy number per reaction.
Results
Design of serotype specific primers—probes for different BTV ‘types’
Sequence data generated for Seg-2 of multiple field, reference and vaccine strains as well as
those available publically in GenBank (S1 Table), were compared to select regions unique to
each of the virus types for the design of primers and probes that could be used to distinguish
and detect each of the 27 + 1 BTV serotypes (Table 2).
The sequences and positions for the serotype-specificprimers for BTV serotypes 1–27 and
putative BTV-29 are given in Table 2. Seg-2 sequence data for assay design for putative BTV28
was unavailable. In some cases (e.g. BTV-7, -18, -21 and -24) the number of available virus
strains, topotypes and / or sequences for each serotype is limited. This imposes limits on the
designs of the current assays, as well as on their evaluation and testing, suggesting that in order
to maintain their efficiency the re-design of some assays may be necessary, as additional iso-
lates and new topotypes of each serotype become available.
In some cases, for example during testing of the BTV-1 specific assays, some of the eastern
topotype strains from Australia (AUS2003/01, AUS2005/02, AUS2009/02) were not detected
by the original primers and probes. The type 1 assay was therefore redesignedwith a new
probe and three out of four primers (Table 2). Similarly the BTV-4, BTV-12 and BTV-21
assays were redesigned to maintain their efficiency for the detection of Indian, Zimbabwean
and Brazilian strains (Table 2).
Evaluation of RT-PCR assays targeting Seg-2, for type-specificity
The RNAs of the 27 monotypic BTV reference strains (BTV-1 to 24, -26, -27 and -29), were
tested in triplicate, with ‘typing-assays’ targeting Seg-2 of each BTV serotypes (S2 Table). Due
to non-availability of RNA for BTV-25 only sequence based comparison/evaluationwas done
for this serotype. As the sequence data for BTV-28 was not available, the assay for this serotype
could not be designed. In every case amplification was only observedwith the homologous
assay confirming the specificity of the assays for each serotype (S2 Table). The specificity of the
assays was further evaluated using field and/or vaccine strain isolates of each serotype, where
possible representing different topotypes collected from diverse geographic locations (from the
ORC). Positive signals were only obtained with the homologous serotype (S2 Table).
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RT-PCR ‘typing’ results for majority of the isolates tested were subsequently verified by
sequencing and phylogenetic analyses of Seg-2 (S2 Table). With some strains the original prim-
ers and probes (as mentioned in table 2) showed relatively poor reactivity. These included
some of the isolates of BTV-1 from Australia (AUS1996/03; AUS2003/01; AUS2005/02;
AUS2009/02) and BTV-4 strains isolated in 2014 from Southern India (IND2014/24), BTV-12
from India (IND2012/01), Brazil (BRA2002/01) and Zimbabwe (ZIM2003/04) and BTV-21
from India (IND2007/09) (S1 Table). The Seg-2 sequence data from these strains showed varia-
tions in the primer and/or probe ‘foot-prints’. Additional sets of primers and probes were
therefore designed and tested for RNA isolated from blood and cell culture grown samples of
these serotypes (Table 2).
Nucleic acid preparations derived from uninfected hosts species (sheep and cattle blood and
C. sonorensis) or uninfected cell culture supernatants (KC cells, BHK cells and Vero cells), or
dsRNA from other closely related Orbivirus species (EEV, PHSV, EHDV and AHSV) (S2
Table) gave ‘no Ct’ values in any of the type-specific assays. Sequence comparison of Seg-2
sequence data for 29 Orbivirus species [44], indicated that neither primers nor probes of the
BTV type-specific assays, would bind to, or amplify their RNA.
Some of the BTV strains originating from India, Israel, Turkey, Europe and, Africa, were
tested using serotype-specificTaqMan probe based qRT-PCR assays giving positive results for
more than one serotype, reflecting the co-circulation of multiple serotypes [44]. For example,
The Indian isolate IND2005/06 contains BTV-2 and BTV-9; Indian isolate IND2005/05 con-
tains BTV-1, BTV-10 and BTV-23; Israeli isolate (ISR2010/22) contains BTV-15 and BTV-8;
isolate ISR2010/16 contains BTV-4 and BTV-8. Isolates TUR2000/06 and TUR2000/07 from
Turkey contain BTV-9 and BTV-16 [44]. These real-time RT-PCR data were confirmed by
conventional Seg-2 specific qRT-PCR assay [21] and Seg-2 sequencing of the mixed BTV
strains, showing more than one distinctive consensus sequences in each case. Comparison of
the sequence data to the Seg-2 dataset of the 29 BTV reference strains, confirmed the real-time
RT-PCR typing results.
Use of RT-PCR assays for typing of BTV isolates from disease
outbreaks
The type-specific qRT-PCR assays describedhere, were used for the primary identification, or
confirmation of BTV serotype for multiple (>1000) diagnostic samples, and field isolates of
BTV. These type specific qRT-PCR assays were used during August—September 2006 for the
identification of BTV-8 in clinical samples from animals in the Maastricht region of northern
Europe, and again in 2007 from the UK. Late in 2008/early 2009, BTV-6 was identified in the
Netherlands [11], BTV-11 in Belgium [57], BTV-25 in Switzerland [17] and BTV-26 in Kuwait
[14], BTV-27 in Corsica [13], and BTV-29 from South Africa [12]. The assays and primers
describedhere are now in routine use in the OIE reference laboratory at The Pirbright Institute,
to detect and identify any of the BTV serotypes as listed on the ORC web pages [44] in diagnos-
tic samples. The results of these assays can be (are) followed by full genome sequencing and
phylogenetic analysis of representative samples from each outbreak, to confirm serotype, and
identify topotype, and genotype (revealing the lineage / origins of each genome segment and
identifying reassortant strains [10, 28].
The BTV serotypes involved in outbreaks that occurred in southern India during 2014 were
identified using these qRT-PCR methods, including BTV-2, BTV-4 and BTV-12 (Maan et al—
unpublished data). BTV-1 (SPA2014/08), and BTV-4 (SPA2014/06, SPA2014/07) were identi-
fied in Spain and the BTV-4 outbreak that occurred in South-eastern Europe during 2014 and
2015, were all identified in this way (BUL2014/01 to BUL2014/14; KOS2014/04 to KOS2014/
BTV Typing qRT-PCR Assays
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09) (S2 Table). Viruses were also isolated from bovine semen samples collected in 2011 from
Brazil. One of the isolates (BRA2011/02), contained BTV-4, BTV-8, BTV-10 and BTV-16,
while another isolate (BRA2011/01) contained BTV-4 and BTV-10 (Gasparini et al—in prepa-
ration) (S2 Table). This provides the first report of BTV-8, BTV-10 and BTV-16 in Brazil.
Previously exotic serotypes that were identified using these techniques, include: BTV-5 and
-24 in India during 2014 (Hemadri et al—unpublished data; [60]; BTV-1, -3, -5, -6, -14, -19,
-22 and -24 from the Americas during 2006–2007 [46]; BTV-1, -4, -8 and -16 from Oman;
BTV-15 and BTV-24 from Israel [61]; BTV-2, -5, and -7 from Australia (S2 Table; Peter Kirk-
land—Personal communication).
Analytical sensitivity and efficiency
RNA of the homologous BTV serotype was detected by all of the ‘typing’ assays. A selection of
the assays for the European serotypes (BTV-1, -2, -4, -6, -8, -9, -11, and -16) were tested for
their sensitivity and efficiency. Plasmid DNA corresponding to homologous European BTV
serotype Seg-2 RNA targets were detected by respective ‘typing’ assays, at all nine dilutions
down to 2–11 copies (S3a–S3h and S4 Tables).
Efficiency rates were calculated for the different European serotype typing assays, on the
bases of dilutions series of dsRNA, giving values between 95–102% (S4 Table) reflected by a
range of slope values (between -3.2 and -3.4). All eight of the Seg-2 assays for European sero-
types that were tested against their homologous serotypes showed linearity (R2> 0.99) (S4
Table).
Discussion
Bluetongue virus causes severe and economically important diseases in domesticated and wild
animals. Introduction of these viruses into areas which are usually free from the disease having
immunologically naïve populations of susceptible host can cause highmorbidity and mortality
[62]. Even in endemic areas, BTV can cause massive reduction in overall productivity of ani-
mals [63]. Apart from emergence of new reassortant strains with novel characteristics,massive
genetic and antigenic diversity among different serotypes/typesmake the prevention and con-
trol of BTV very difficult.
To enable the fast and accurate identification and typing of BTVwe report the development
of a complete panel of ‘TaqMan’ fluorescence-probe based quantitative real-time type-specific
RT-PCR assays. These real-time RT-PCR assays are considerably more sensitive than the con-
ventional RT-PCR assays previously published for typing BTV RNA [21, 42, 64]. There was
also no evidence for cross-amplification of RNA from heterologous serotypes by any of the
type-specific assays (Seg-2). However, the very high specificity of real-time RT-PCR primers
and probes can lead to false negative results, particularly with strains containing sequence vari-
ations in the target gene [65]. Although very recently a set of real-time assays for typing 22 dif-
ferent BTV types have been reported by [66], the combination of type-specific diagnostic
assays describedhere provides a more complete set of tools for rapid and accurate detection
and identification of BTV to support surveillanceprogrammes globally. As previously demon-
strated for BTV, real-time RT-PCR assays are the most sensitive and reliable methods (that are
currently available) for orbivirus detection and typing [67–69]. All of the type-specific assays
targeting Seg-2 reported here are highly efficient, doubling amplicon quantity during each
round of amplification in the geometric phase of the reaction and can detect similar levels of
RNA to other published real-time PCR assays [40, 41]. The large number of BTV isolates that
were available for this study from the ORC, have made the wider validation of these assays pos-
sible. However, owing to high genetic diversity in these viruses it is very likely that refinement
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of these assays will be required in future. Eastern and western strains of the same serotype for
BTV-1, 2, 9 and 16, were too divergent for a single set of ‘common’ type-specific primers and
probe in each case (Table 3). Hence the assays for these serotypes use a duplex format to allow
amplification of the more diverse strains (e and w) within these types (S1 Table). Some of the
BTV-1 strains from Australia and BTV-4, BTV-12 and BTV-21 isolated from recent outbreaks
in India showed poor reactivity with the original pairs of primers and probes (Table 2) hence
the primers for these serotypes were upgraded as listed in Table 2. In certain serotypes (BTV-7,
-18, -20, -21, -25, -26, -27 and -29) the specificity of amplification was not widely validated as
only limited number of isolates, were available for testing, leaving some uncertainty concerning
their specificitywith more diverse strains of the same types. The diagnostic specificity of the
typing assays describedhere, relates primarily to their inability to detect Seg-2 of non-homolo-
gous types, while still detecting all available isolates from the homologous BTV type. If a novel
isolate of the virus is identified (e.g. by the virus-species-specificassays) that fails to amplify
using the typing assays, it should be sequenced (Seg-2) to provide a basis for further develop-
ment/refinement of the relevant primers and probes. Similar problems have been addressed
with conventional and real-time RT-PCR assays detecting Seg-2 of BTV, in order to maintain
their specificity and sensitivity [21].
Previous serologicalmethods have detectedmultiple serotypes of BTV co-circulating in the
endemic regions. The qRT-PCR assays describedhere have been used to identify several iso-
lates containing mixed BTV types, which could not have been unambiguously typed by VNT.
Recently several novel BTV types (BTV-25–26–27) have been identified primarily by RNA
sequence basedmethods, including RT-PCR assays, and subsequently confirmed as novel sero-
types by serological typing methods [13, 14, 17]. Additional virus strains / isolates have been
identified that represent two additional putative BTV serotypes. These include BTV-28 from
the Middle East (Peter Mertens—Personal communication); and a putative BTV-29 isolated
from an alpaca in South Africa [12]. It has been suggested that it would be useful to set absolute
values for nucleotide and amino acid variations in Seg-2 and VP2 that can be used to define
BTV serotype (Peter Mertens—Personal communication). Current data indicate that viruses
within the same serotype can show up to 31.6% nucleotide variation, and 27.4% amino acid
variation in Seg-2 and VP2 respectively [11, 18]. Viruses belonging to different serotypes can
show up to 71.5% nucleotide identity and 77.8% aa identity, with a minimum of 28.5% nucleo-
tide variation and 22.2% aa variation between serotypes [11, 18]. There is clearly an overlap
that makes the identification of clear limits to serotype variation difficult, but it is important to
note that this overlap is caused primarily by the existence of different topotypes of Seg-2 and
VP2 within individual serotypes. However, if the major different topotypes (for example the
eastern and western groups) are considered separately, then the level of variation for isolates
within each serotype (also belonging to the same topotype), drops to a maximum of 21.8%
nucleotide variation and 13.9% aa variation. This then gives a clear difference of 7.7% nt and
8.3% aa difference between the levels of variation for distinct serotypes and those within the
same serotype and topotype. This potentially gives us useful and clear guidance for the identifi-
cation of the existing serotypes, where both eastern and western strains have already been iden-
tified and sequenced.However, if a novel isolate is discovered that fall into this gap, it could
represent either a novel serotype that is closely related to, but distinct from, other established
serotypes, or it could represent an isolate of an existing serotype, but belonging to a different
and distinct major topotype. The novel putative serotypes BTV-28 and -29 show significant
sequence variations in Seg-2/VP2when compared to isolates of previously recognisedBTV
serotypes, with a level of identity (up to 69.5%), confirming that they represent novel types.
Even though the serological techniques are relatively insensitive and prone to cross-reactions,
they remain as a gold-standard for serotype identification, particularly for confirmation of
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novel serotypes. Once identified in this way these new viruses would become a ‘reference
strains’, either for a novel serotype, or of an existing serotype but within a newmajor topotype.
This also confirms that we need to identify reference strains for each serotype, within each of
the major BTV topotypes.
To summarize, the ‘TaqMan’ probe based real-time RT-PCR basedmethods describedhere,
represent fast, robust and reliable tools for the detection and typing of BTV. Together with
sequencing studies it will help us to better understand the molecular epidemiology (distribu-
tion and spread) of these viruses. This system will support investigations of BTV outbreaks and
can help to devise strategies for timely implementation of control measures for BTV, particu-
larly vaccination programmes.
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